Vision on the Road: Vision Rehabilitation for Driving After Stroke (NCT07147660) | Clinical Trial Compass
RecruitingNot Applicable
Vision on the Road: Vision Rehabilitation for Driving After Stroke
Norway52 participantsStarted 2025-03-28
Plain-language summary
The goal of this clinical trial is to learn if vision training works to improve functional vision in people with visual field loss after stroke. The investigators want to know more about how people perceive their own functional vision and ability to compensate for visual field loss in daily activities.
The main questions the study aims to answer are:
* Does vision training improve dimensions of functional vision?
* How does vision training affect the participants's perception of functional vision and the ability to compensate for visual field loss? Researchers will compare the effect of home-based vision training to standard care (no vision training) on functional vision.
Participants will:
* Participate in home-based vision training or standard care for 8 weeks
* Be contacted once a week by phone
* Keep a training diary
Who can participate
Age range
20 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Adults aged 20-85 years with a visual field defect following stroke
* Norwegian Class 1 driving licence revoked no more than five years ago
* Speak a Scandinavian language
* Able to provide written informed consent
* Motivated and willing to participate in study activities for a total of 20 to 28 weeks
* Own a personal computer (for digital follow-up and online vision training)
* Able to travel to Oslo for data collection
Exclusion criteria:
* Presence of strabismus and/or visual neglect
* Eye disease or other health conditions that do not meet the health requirements for a Norwegian Class 1 driver's license
* Cognitive impairment, dementia, severe psychiatric diagnosis, or inability to provide written informed consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Visual Field measured with Saccadic Reaction Time in ms
Timeframe: Two measurements (1 hour between assessments) at baseline, post-intervention (8 weeks) (post-intervention group A, post-control/pre-intervention group B) and a final measurement (long-term effect) 12 weeks after intervention (20 weeks after baseline).